These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 6357431

  • 1. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J.
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [Abstract] [Full Text] [Related]

  • 2. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
    Joraku A, Homhuan A, Kawai K, Yamamoto T, Miyazaki J, Kogure K, Yano I, Harashima H, Akaza H.
    BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
    [Abstract] [Full Text] [Related]

  • 3. Preoperative intralesional Bacillus Calmette-Guérin for mammary adenocarcinoma in rats.
    Lee YT.
    Cancer Res; 1977 Oct; 37(10):3679-83. PubMed ID: 908015
    [Abstract] [Full Text] [Related]

  • 4. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA, Chin JL, Batislam E, Karlik SJ, Garcia B, Skamene E.
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [Abstract] [Full Text] [Related]

  • 5. Effects of methanol extraction residue and therapeutic irradiation against established isografts and simulated local recurrence of mammary carcinomas.
    Yron I, Cohen D, Robinson E, Haber M, Weiss DW.
    Cancer Res; 1975 Jul; 35(7):1779-90. PubMed ID: 1093676
    [Abstract] [Full Text] [Related]

  • 6. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF, Lamm DL.
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
    Shapiro A, Ratliff TL, Oakley DM, Catalona WJ.
    Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
    [Abstract] [Full Text] [Related]

  • 9. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
    Ratliff TL, Palmer JO, McGarr JA, Brown EJ.
    Cancer Res; 1987 Apr 01; 47(7):1762-6. PubMed ID: 3545453
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Systemic antitumor activity of Bacillus Calmette Guerin and purified protein derivatives against tumors in mice having tuberculin allergy.
    Abe S, Saito M, Yamazaki M, Mizuno D, Tsumita T.
    Jpn J Exp Med; 1978 Oct 01; 48(5):455-7. PubMed ID: 372638
    [No Abstract] [Full Text] [Related]

  • 12. Comparative antitumor effects of Corynebacterium parvum, Bordetella pertussis, Bacillus Calmette-Guérin, and levamisole alone or in combination with cyclophosphamide in the CaD2 murine mammary adenocarcinoma system.
    Purnell DM, Bartlett GL, Kreider JW, Biro TG, Kontra J.
    Cancer Res; 1979 Dec 01; 39(12):4838-42. PubMed ID: 498111
    [Abstract] [Full Text] [Related]

  • 13. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr 01; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of Bacillus Calmette-Guérin-induced suppression of metastases in a poorly immunogenic fibrosarcoma.
    Liotta LA, Kleinerman J, Saidel GM.
    Cancer Res; 1976 Sep 01; 36(9 pt.1):3255-9. PubMed ID: 788897
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid.
    Youn JK, Lacour F, Hue G.
    Cancer Res; 1982 Nov 01; 42(11):4706-11. PubMed ID: 7127305
    [Abstract] [Full Text] [Related]

  • 16. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
    Fisher B, Gebhardt M.
    Cancer Treat Rep; 1978 Nov 01; 62(11):1919-30. PubMed ID: 728912
    [Abstract] [Full Text] [Related]

  • 17. Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma.
    Kreider JW, Bartlett GL, Boyer CM, Purnell DM.
    Cancer Res; 1979 Mar 01; 39(3):987-92. PubMed ID: 427785
    [Abstract] [Full Text] [Related]

  • 18. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin.
    Dubois JB, Serrou B.
    Cancer Res; 1976 May 01; 36(5):1731-4. PubMed ID: 773530
    [Abstract] [Full Text] [Related]

  • 19. Defining bacillus Calmette-Guerin refractory superficial bladder tumors.
    Herr HW, Dalbagni G.
    J Urol; 2003 May 01; 169(5):1706-8. PubMed ID: 12686813
    [Abstract] [Full Text] [Related]

  • 20. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A, Beyríe Tamayo W, Gozá León F, Muñoz YI.
    Arch Esp Urol; 2004 May 01; 57(6):606-18. PubMed ID: 15382436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.